Screener
Jazz Pharmaceuticals JAZZ EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed November 5, 2025. Open the filing →
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001232524-25-000074
FAQ
- What is Jazz Pharmaceuticals's EBITDA margin?
- Jazz Pharmaceuticals (JAZZ) reported EBITDA margin of -10.9% in Q3 2025.
- How has Jazz Pharmaceuticals's EBITDA margin changed year-over-year?
- Jazz Pharmaceuticals's EBITDA margin decreased by 164.1% year-over-year, from 17% to -10.9%.
- What is the long-term trend for Jazz Pharmaceuticals's EBITDA margin?
- Over 4 years (2020 to 2024), Jazz Pharmaceuticals's EBITDA margin has grown at a 2.3% compound annual growth rate (CAGR), from 16.8% to 18.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Jazz Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude